HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fazio, S. Articles by Linton, M. F. Search for Related Content PubMed PubMed Citation Articles by Fazio, S. Articles by Linton, M. F.

Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein?

¹ Departments of Medicine,
² Pathology, and
³ Pharmacology Vanderbilt University Medical Center, Nashville, TN USA

SUMMARY

Conventional wisdom suggests that halting or reversing long-term atherosclerosis requires increasing the amount of circulating high-density lipoprotein (HDL) coursing through the vasculature. However, recent evidence seems to indicate that reducing the size of cholesterol-containing lipid plaques might be accomplished by methods that either do not raise or, in fact, lower the amount of circulating HDL. Carriers of apoAI_Milano, a variant of apoprotein AI (a component of HDL), have reduced levels of circulating low-density lipoprotein (LDL). Intriguingly, these individuals have reduced amounts of circulating HDL and total apoAI. Infusions of the ApoAI_Milano variant given to patients with coronary atherosclerosis appear to lead to disease regression and reduced plaque size. However, larger studies are required to provide definitive proof of apoAI_Milano’s benefits. What is certain is that attention should be focused on the removal of cholesterol from plaques rather than simply desiring to raise HDL concentrations in patients.

This article has been cited by other articles:

				J. S. L. Tan, J. J. Wang, V. Flood, and P. Mitchell Dietary Fatty Acids and the 10-Year Incidence of Age-Related Macular Degeneration: The Blue Mountains Eye Study Arch Ophthalmol, May 1, 2009; 127(5): 656 - 665. [Abstract] [Full Text] [PDF]

				J. S. L. Tan, P. Mitchell, A. Kifley, V. Flood, W. Smith, and J. J. Wang Smoking and the Long-term Incidence of Age-Related Macular Degeneration: The Blue Mountains Eye Study Arch Ophthalmol, August 1, 2007; 125(8): 1089 - 1095. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]